Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.2K Hold
196
﹤0.01% 835
2026
Q1
$12.3K Buy
196
+10
+5% +$696 ﹤0.01% 810
2025
Q4
$12.3K Hold
186
﹤0.01% 838
2025
Q3
$12.5K Hold
186
﹤0.01% 797
2025
Q2
$16.2K Hold
186
﹤0.01% 706
2025
Q1
$12.7K Hold
186
﹤0.01% 756
2024
Q4
$14.5K Buy
186
+50
+37% +$3.7K ﹤0.01% 731
2024
Q3
$9.12K Sell
136
-4,454
-97% -$366K ﹤0.01% 774
2024
Q2
$520K Hold
4,590
0.02% 150
2024
Q1
$637K Hold
4,590
0.03% 149
2023
Q4
$570K Buy
4,590
+750
+20% +$76.6K 0.03% 153
2023
Q3
$358K Hold
3,840
0.02% 170
2023
Q2
$493K Hold
3,840
0.02% 155
2023
Q1
$446K Hold
3,840
0.02% 154
2022
Q4
$435K Hold
3,840
0.02% 155
2022
Q3
$309K Hold
3,840
0.02% 171
2022
Q2
$286K Hold
3,840
0.02% 177
2022
Q1
$491K Buy
+3,840
New +$420K 0.02% 159

Other funds holding DXCM

Eastern Bank's DXCM Position: Q2 2026 in Review

Eastern Bank held its DexCom (DXCM) position steady in Q2 2026 at 196 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #835.

Eastern Bank first reported a position in DXCM in Q1 2022 and has held it in 18 quarters since. The position peaked at $637K in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Eastern Bank held 196 shares of DexCom worth $13.2K as of Q2 2026.
  • Eastern Bank left its DexCom share count unchanged in Q2 2026.
  • DexCom made up ﹤0.01% of Eastern Bank's portfolio in Q2 2026, its #835 holding.
  • Eastern Bank first reported a position in DexCom in Q1 2022 and has held it in 18 quarters since.
  • Eastern Bank's DexCom position peaked at $637K in Q1 2024.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Eastern Bank's 13F filing for Q2 2026, filed 1 Jul 2026.